In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
Original Innovation, Science Oriented
Globally-integrated R&D process
Technology system encompassing the entire lifecycle of antibodies
Innovation-driven Biopharma
China’s leading innovative biopharmaceutical company
Established in December, 2012
Therapeutic Area
Oncology
Toripalimab (PD-1), Tifcemalimab (BTLA)…
Autoimmune
Adalimumab (TNF-α), JS005 (IL-17A), UBP1213sc (BLyS)
Metabolic
Ongericimab (PCSK9), JS103 (Uricase), JS401 (ANGPTL3)…
Neurological
Infectious
Etesevimab (S protein), Deuremidevir Hydrobromide (RdRp)…
Therapeutic Area
Oncology
Autoimmune
Metabolic
Neurological
Infectious
Learn more
2012.12
Junshi Biosciences was established in Shanghai, the PRC.
2018.12
Toripalimab（TUOYI® , JS001）was granted marketing approval by the NMPA.
2023.10
Toripalimab（LOQTORZI™）was granted marketing approval by the FDA.
Learn more
News Center
Mar 26, 2025
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
>Toripalimab has become the first and only approved immuno-oncology treatment for NPC in Singapore
View details
Mar 26, 2025
jinnianhui金年会生物宣布特瑞普利单抗在新加坡获批
>特瑞普利单抗是新加坡首个且唯一获批用于鼻咽癌的肿瘤免疫治疗药物
View details
Nov 16, 2024
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC
View details
Oct 12, 2024
Junshi Biosciences Announces Ongericimab’s NDA Approval in China
>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)
View details
